How does S‑(–) metoprolol differ from racemic metoprolol, and are there specific recommendations, dose adjustments, or safety concerns for prescribing it to patients?

S(-) Metoprolol vs Racemic Metoprolol: Clinical Recommendation

S-metoprolol at 50 mg is therapeutically equivalent to racemic metoprolol 100 mg and offers theoretical advantages in cardioselectivity and drug interactions, but lacks robust outcomes data—stick with standard racemic metoprolol formulations unless your patient has specific CYP2D6 concerns or problematic drug interactions.

Key Pharmacologic Differences

S-metoprolol is the isolated active enantiomer that provides the beta-1 blocking activity, while racemic metoprolol is a 50:50 mixture of S- and R-enantiomers 1. The R-enantiomer exhibits beta-2 blocking activity and contributes no therapeutic benefit for cardiovascular indications 1. This means racemic metoprolol is essentially "two different drugs in a fixed 1:1 ratio" where you're administering 50% unnecessary medication 1.

Pharmacokinetic Considerations

Both enantiomers are metabolized by CYP2D6, but the metabolism is stereoselective 2, 3. In CYP2D6 poor metabolizers (8% of Caucasians, 2% of other populations), metoprolol concentrations increase several-fold, and cardioselectivity decreases 2. The R-enantiomer has greater interaction potential with CYP2D6 inhibitors 1.

Available Clinical Data

The evidence base for S-metoprolol is extremely limited:

• One open-label comparative study (n=100) showed S-metoprolol 50 mg once daily was equivalent to racemic metoprolol 100 mg for angina control, with a trend toward higher response rates (72% vs 62%, not statistically significant) 4
• Similar reductions in blood pressure and heart rate were observed in both groups 4
• Adverse event profiles were comparable between groups 4

Critical limitation: No large randomized controlled trials, no mortality data, no heart failure outcomes, and no inclusion in major cardiovascular guidelines 5, 6.

Guideline Position

Neither the 2022 AHA/ACC/HFSA Heart Failure Guidelines nor the 2024 ACC/AHA Atrial Fibrillation Guidelines mention S-metoprolol 5, 6. The guidelines specifically recommend "metoprolol succinate extended release" with target doses of 200 mg daily for heart failure, based on mortality reduction trials 5. These landmark trials used racemic formulations—S-metoprolol has never been studied for mortality or morbidity outcomes.

Dose Equivalence

If prescribing S-metoprolol:

• 50 mg S-metoprolol = 100 mg racemic metoprolol 1, 4
• Use half the racemic dose for equivalent beta-1 blockade
• No specific dose adjustment guidelines exist beyond this 1:2 ratio

Safety Profile

Theoretical advantages 1:

• Higher cardioselectivity (less beta-2 blockade) may be safer in COPD, diabetes, and peripheral vascular disease
• Reduced CYP2D6 interaction potential in patients taking inhibitors (fluoxetine, paroxetine, quinidine)
• May be preferable in hepatic insufficiency due to less metabolic burden

Reality check: The clinical study showed no significant difference in adverse events between S-metoprolol and racemic metoprolol 4. The theoretical benefits have not translated into demonstrable clinical superiority.

Practical Recommendation Algorithm

Use racemic metoprolol (standard formulations) if:

• Treating heart failure with reduced ejection fraction (only racemic studied for mortality) 5
• Treating post-MI patients (only racemic studied for mortality) 2
• Patient needs guideline-directed medical therapy with proven outcomes

Consider S-metoprolol only if:

• Patient is on multiple CYP2D6 inhibitors with problematic interactions
• Patient is a known CYP2D6 poor metabolizer with documented intolerance to racemic formulation
• Cost is equivalent (unlikely) and patient specifically requests it

Never use S-metoprolol for:

• Heart failure (no outcomes data)
• Post-MI (no outcomes data)
• Any condition where mortality benefit is the goal

Critical Pitfalls

1. Marketing vs. Evidence: Drug companies promote S-metoprolol as "more selective" but this hasn't translated to better clinical outcomes 1, 4

2. Dose Confusion: If switching from racemic to S-metoprolol, you must halve the dose—prescribing equivalent mg doses would double the beta-blockade

3. Guideline Non-Compliance: Using S-metoprolol for heart failure means deviating from evidence-based guidelines that specify metoprolol succinate 5

4. CYP2D6 Variability: Even with S-metoprolol, CYP2D6 poor metabolizers will have significantly higher exposure and may lose cardioselectivity 2, 3

5. No Long-Term Data: Recent studies show unexpected enantiomer ratio inversions in long-term therapy, suggesting complex metabolic interactions we don't fully understand 7, 8

Bottom Line

S-metoprolol is pharmacologically rational but clinically unproven. The 2022 heart failure guidelines achieved a 34% relative risk reduction in mortality with racemic metoprolol succinate 5—that's real data affecting real outcomes. S-metoprolol offers theoretical elegance without proven superiority. In evidence-based medicine, proven mortality benefit trumps pharmacologic purity.